Lumiracoxib

Chemical structure of Lumiracoxib

Lumiracoxib is a nonsteroidal anti-inflammatory drug (NSAID) that belongs to the class of cyclooxygenase-2 (COX-2) inhibitors. It is used for the treatment of osteoarthritis and acute pain. Lumiracoxib is known for its selective inhibition of the COX-2 enzyme, which plays a role in the inflammatory process.

Mechanism of Action

Lumiracoxib works by selectively inhibiting the COX-2 enzyme, which is responsible for the synthesis of prostaglandins that mediate inflammation, pain, and fever. Unlike traditional NSAIDs, which inhibit both COX-1 and COX-2, lumiracoxib's selectivity for COX-2 reduces the risk of gastrointestinal side effects associated with COX-1 inhibition.

Pharmacokinetics

Lumiracoxib is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 2 hours post-dose. It is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system, and is excreted mainly in the urine.

Clinical Use

Lumiracoxib is indicated for the relief of symptoms associated with osteoarthritis, such as pain and inflammation. It is also used for the management of acute pain in various conditions. However, its use is limited due to concerns about cardiovascular safety and liver toxicity.

Safety and Side Effects

Common side effects of lumiracoxib include gastrointestinal discomfort, headache, and dizziness. Serious side effects may include cardiovascular events such as myocardial infarction and stroke, as well as liver damage. Due to these risks, lumiracoxib has been withdrawn from the market in several countries.

Regulatory Status

Lumiracoxib was approved for use in several countries but has faced regulatory challenges due to safety concerns. It has been withdrawn from the market in many regions, including the European Union and Australia, due to reports of severe liver injury.

Related pages

• Nonsteroidal anti-inflammatory drug
• Cyclooxygenase-2 inhibitor
• Osteoarthritis